E. coli vs. Salmonella: Infection Mechanisms and Resistance

E. coli and Salmonella diverged from the same ancestor roughly 120 million years ago, yet they have evolved strikingly different strategies for infecting humans and resisting the drugs used to treat them.¹ The core split comes down to location: pathogenic E. coli strains generally cling to the outside of your gut cells and do their damage from there, while Salmonella breaks in, hides inside host cells, and can spread through the body. That single difference in lifestyle shapes nearly everything else about how each bacterium causes disease, evades your immune system, and picks up antibiotic resistance.

A Shared Toolkit Used in Different Ways

Both organisms belong to the family Enterobacteriaceae, and their genetic overlap is considerable. They share a critical piece of infection hardware called a type III secretion system, essentially a molecular syringe that injects bacterial proteins directly into the host cell’s interior. These injected proteins hijack the cell’s internal scaffolding to benefit the pathogen.² But what each bacterium does with that shared tool diverges sharply.

Enteropathogenic E. coli (EPEC), one of the most studied disease-causing strains, uses its secretion system to latch tightly onto the surface of intestinal cells and remodel their structure from the outside. The bacterium pushes the cell membrane up into a pedestal beneath itself, anchoring in place while it disrupts the gut lining. It never needs to move inside the cell. Salmonella, by contrast, uses the same general type of injection system to trigger the host cell to engulf it voluntarily, then takes up residence inside a specialized compartment within the cell.³ Both pathogens manipulate the host’s own cytoskeleton to achieve their goals, but toward opposite ends: one stays out, the other moves in.⁴

How Salmonella Survives Inside Your Cells

Salmonella’s decision to live intracellularly creates a problem that E. coli never has to solve: surviving the immune system’s front-line killers. When your body detects Salmonella, immune cells called macrophages try to swallow and destroy the bacteria by trapping them in an acidic compartment. Most bacteria die in that acid bath. Salmonella does something unexpected: instead of fighting the drop in pH, it deliberately acidifies its own interior to match, which helps it secrete the effector molecules it needs to remodel the compartment into a livable space.⁵ This gives Salmonella a protected niche from which it can multiply and eventually spread to other organs, which is why Salmonella infections are more likely to become systemic than most E. coli infections.

Pathogenic E. coli strains, because they remain outside cells, face a different set of immune pressures. They are more exposed to circulating antibodies and complement proteins in the gut lumen, so they rely on surface structures and toxins to maintain their foothold. Shiga toxin-producing E. coli (STEC), for example, releases toxins that damage blood vessel lining cells in the kidneys and intestines, causing the severe complications associated with outbreaks. Salmonella produces its own cytotoxins, but these are immunologically distinct from the Shiga-family toxins that E. coli uses.⁶ In other words, even their chemical weapons have diverged substantially since the two lineages split.

Biofilms and Environmental Persistence

Both E. coli and Salmonella form biofilms, the slimy, structured communities that let bacteria stick to surfaces and resist cleaning. They even use overlapping molecular building blocks to do it, particularly curli fibers and cellulose. In both species, curli fibers are essential for building a proper three-dimensional biofilm. A Salmonella mutant lacking curli is severely impaired in biofilm formation, and one missing the global regulator that controls curli production fares even worse. A cellulose-deficient Salmonella mutant can still form loose cell clumps but cannot build a full, continuous biofilm.⁷

E. coli follows a similar pattern, with curli and cellulose working together synergistically. Knocking out both curli and cellulose production in pathogenic E. coli strains reduced their ability to stick to human intestinal cells by about 85 to 88 percent, a much larger drop than losing either component alone. The same cooperative effect held when researchers tested adherence to cow colon tissue, which matters because cattle are a major reservoir for certain dangerous E. coli strains.⁸ Biofilms are clinically important because bacteria embedded in them tolerate antibiotics at much higher concentrations than free-floating cells, and they are notoriously difficult to eliminate from food-processing equipment and medical devices.

Antibiotic Resistance and the Mechanisms Behind It

Drug resistance in both species is a serious and growing public health threat, but the specific resistance tools each pathogen reaches for can differ, even when they share the same core hardware.

The most clinically significant efflux pump in both E. coli and Salmonella Typhimurium is the AcrAB-TolC complex, a molecular vacuum cleaner that actively pushes a wide variety of antibiotics back out of the bacterial cell before they can do their job. Blocking this pump allows antibiotics to accumulate inside the cell and regain their effectiveness, which is why it has become a target for drug discovery efforts.⁹ This shared pump contributes to both the inherent, baseline resistance and the evolved, acquired resistance seen in these bacteria.

Where the two species diverge more clearly is in their relationship with carbapenems, the powerful last-resort antibiotics reserved for serious infections. In E. coli, carbapenem resistance driven by the loss of outer membrane pore proteins (porins) is relatively well documented. In Salmonella, this mechanism is rarely reported. Recent genetic work identified two specific porins whose loss is crucial for the development of carbapenem resistance in Salmonella strains that already produce certain enzymes capable of breaking down other antibiotics.¹⁰ The finding matters because it means Salmonella may have a latent capacity for carbapenem resistance that has simply not been widely exploited yet. Most Salmonella serovars carry seven porin-related genes, any combination of which could potentially be lost under the right selective pressure.

Colistin resistance tells a somewhat different story. Colistin is another last-resort antibiotic, and resistance to it mediated by a gene called mcr-1 was first identified on a mobile piece of DNA (a plasmid) in E. coli, raising alarm because plasmid-borne genes spread far more easily between bacteria than chromosomal mutations do.¹¹ The mcr family of genes has since been found in multiple bacterial species, and its mobility is what makes it so dangerous: it can jump not just between E. coli strains but potentially into Salmonella and other gut bacteria as well.¹²

Passing Resistance Genes Back and Forth

One of the most unsettling aspects of resistance in these two species is how readily they swap genetic material. E. coli and Salmonella coexist in the guts of livestock and humans, and when one picks up a resistance gene, it can pass that gene to the other through a process called conjugation, essentially forming a temporary bridge between cells and transferring a plasmid across. Laboratory studies have confirmed that susceptible E. coli can acquire resistance genes from resistant Salmonella strains, and that conjugation is the most efficient route for this exchange.¹³

The transfer runs in both directions. E. coli has been shown to donate plasmids carrying resistance genes for fluoroquinolones and extended-spectrum cephalosporins directly to Salmonella.¹⁴ This bidirectional exchange means that treating one species with antibiotics can indirectly arm the other. It also means that the gut itself functions as a mixing pot for resistance genes, especially in environments where antibiotics are used heavily, such as intensive livestock farming.

Livestock, Food, and the Reservoir Problem

Both pathogens circulate through the same agricultural pipelines, which amplifies the resistance exchange described above. Cattle, pigs, poultry, and sheep are all recognized reservoirs for drug-resistant strains of both E. coli and Salmonella. A study of sheep and their slaughterhouse environments in the United States confirmed that both the animals and the abattoir itself act as important reservoirs for multidrug-resistant Salmonella and extended-spectrum beta-lactamase-producing E. coli.¹⁵ Animal-origin foods, including meat, milk, eggs, and fish, serve as vehicles for transmitting resistant bacteria and their resistance genes to humans.¹⁶

This shared ecology is a big part of why the resistance problem in E. coli and Salmonella cannot be tackled separately. A resistance gene that emerges on a poultry farm in one species can end up in the other species in a human gut thousands of miles away, having traveled through the food chain, jumped between bacteria along the way, and arrived carrying a combination of resistance factors that no single antibiotic treatment can overcome.

When Infections Reach the Bloodstream

Most E. coli and Salmonella infections stay in the gut and resolve on their own, but both can cause bloodstream infections, and the clinical picture looks quite different for each. A study comparing pediatric bloodstream infections found that children with non-typhoidal Salmonella in their blood were typically older and far more likely to present with fever and diarrhea than children with E. coli bloodstream infections. However, E. coli bloodstream infections were more severe by other measures: children with E. coli were hospitalized longer, had higher inflammatory markers, and were admitted to intensive care at dramatically higher rates, roughly half of E. coli cases versus under five percent of Salmonella cases.¹⁷

This pattern makes sense given the biology. E. coli bloodstream infections often originate from urinary tract infections or abdominal sources, and the strains involved tend to carry virulence factors that provoke intense inflammatory responses. Salmonella bloodstream infections typically arise from gut invasion, and while the bacterium’s ability to survive inside macrophages lets it spread systemically, the initial immune response is often less explosive. Neither is benign. E. coli bacteremia kills through overwhelming inflammation, while Salmonella bacteremia can establish chronic, hard-to-clear infections in bones, joints, and the vascular system.

Your Gut Bacteria as a Defense Against Salmonella

Here is where the relationship between E. coli and Salmonella gets genuinely strange. While pathogenic E. coli strains cause disease, the harmless commensal E. coli that normally live in your gut actually help protect you against Salmonella colonization. Your gut microbiota provides what researchers call colonization resistance: a combination of nutrient competition, antimicrobial peptide production, and immune system modulation that makes it harder for invading pathogens to gain a foothold.¹⁸

Research using mice colonized with defined bacterial communities showed that commensal E. coli blocks Salmonella Typhimurium by competing for galactitol, a sugar alcohol derived from the diet. When other community members, particularly bacteria from the Lachnospiraceae family, consumed most of the simple sugars in the gut, galactitol became the critical remaining fuel source. Commensal E. coli depleted that fuel before Salmonella could use it, starving the invader out.¹⁹ E. coli alone was not enough; it needed the broader microbial community to strip away other nutrients first. This contextual cooperation helps explain why antibiotic treatment, which devastates commensal gut bacteria, often increases susceptibility to Salmonella infection. You lose the team that was holding the line.

Diagnostics and Surveillance

Because E. coli and Salmonella share so much genetic background, distinguishing them and identifying their resistance profiles quickly is a practical challenge in clinical and food-safety laboratories. Traditional culture-based methods work but take time. Microarray platforms that screen simultaneously for dozens of virulence and resistance genes in both species have shown strong agreement between what the genetic test predicts and how the bacteria actually behave when exposed to antibiotics.²⁰ These tools let public-health labs identify not just what species is causing an outbreak, but what drugs it is likely to resist, before the culture results come back. In an era of increasing multidrug resistance, that speed matters.

Whole-genome sequencing has largely superseded earlier microarray approaches for outbreak investigation, but the principle remains the same: you want to know, as fast as possible, which virulence genes and resistance genes are present, so you can predict the clinical course and choose effective treatment. The overlap in resistance gene pools between E. coli and Salmonella makes this surveillance doubly important, since a resistance gene circulating in E. coli on farms today may show up in Salmonella causing human infections tomorrow.

Phage Therapy and Other Alternatives

With conventional antibiotics losing ground, researchers are looking for other ways to fight both pathogens. Bacteriophages, viruses that infect and kill specific bacteria, are one of the most promising alternatives. Experimental studies in poultry have already demonstrated the safety and effectiveness of phage therapy against Salmonella, and phage cocktails (mixtures of several different phages) show particular promise because they reduce the chance that the target bacterium will evolve resistance to a single phage.²¹ Similar work is ongoing for E. coli, particularly for strains that produce extended-spectrum beta-lactamases and are resistant to most standard treatments.

Phage therapy has limitations. Phages tend to be highly specific to particular bacterial strains, so a phage that kills one Salmonella serovar may do nothing to another. Regulatory frameworks for phage products are still catching up, especially outside Eastern Europe, where phage therapy has a longer clinical history. And the same horizontal gene transfer mechanisms that spread antibiotic resistance can, in theory, spread phage-resistance mutations too. Still, in an environment where a growing fraction of both E. coli and Salmonella isolates resist multiple frontline drugs, phages represent one of the few genuinely new weapons in the pipeline, and the agricultural sector, where these bacteria circulate most freely, may be where they are deployed first.